Dabrafenib Monotherapy. NCCP National SACT Regimen. HSE.
Regulatory approval published by the Health Service Executive.
Citation
Regulatory approvals
Approved indications from this document for cancer drugs containing at least one biomarker.
| Indication | Statements |
|---|---|
| Treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. | 2 |
Therapeutic response
Precision oncology relationships for therapeutic response derived from this document.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | BRAF p.V600E | Melanoma | Dabrafenib | |
| Sensitivity (+) | BRAF p.V600K | Melanoma | Dabrafenib |